Skip to main content
Quest Diagnostics

Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing

Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing

Authors: Levy B, Liu J, Iqbal MA, DuPont B, Sahajpal N, Ho M, Yu J, Brody SJ, Ganapathi M, Rajkovic A, Smolarek TA, Boyar F, Bui P, Dubuc AM, Kolhe R, Stevenson RE

Citation: J Mol Diagn. 2024 Jul 18:S1525-1578(24)00157-0. doi: 10.1016/j.jmoldx.2024.06.006. Online ahead of print.

Specialties: Genetics, Women's health, OB, GYN

Related content

Publication
Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era
Conference Presentation
The Proportion of Reportable cfDNA Screening Results for Fetal Aneuploidy in Pregnancies Less Than 10 Weeks Gestation
Audio Podcast
A Commitment to Women’s Health
Test FAQ
QNatal Advanced
Test FAQ
Chromosome Analysis, POC Tissue
Test FAQ
Maternal Serum AFP
Test FAQ
Cystic Fibrosis Screen
Test FAQ
FISH Prenatal Screen

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.